

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193

Status	RECRUITING
Phase	Phase 3
Sponsor	Merz North America, Inc.
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (2)

- Presence of four (medial and lateral, left and right) platysmal bands assessed at screening and baseline.
- A score of Grade 3 ('moderate') or Grade 4 ('severe') on the MAPS-D at maximum contraction by the investigator and participant.

Exclusion (7)

- Hypersensitivity or a history of allergic reaction to botulinum toxin of any serotype or any of their formulation ingredients.
- Any medical condition that may put the participant at increased risk with exposure to botulinum toxin of any serotype, or any disorders that might interfere with neuromuscular function.
- Any serious disease or disorder that could interfere with the safe completion of treatment or with study outcome assessments, or compromise participant safety.
- Botulinum toxin treatment in the face (below the lower orbital rim), jawline, or neck within the last seven months.
- History of lower face surgery, neck or chest surgery, aesthetic procedures, and orthodontic procedures in the past 12 months.

... and 2 more (see full listing online)

Locations (28 total)

Merz Investigative Site, Scottsdale, Arizona, United States
Merz Investigative Site, Encino, California, United States
Merz Investigative Site, Los Angeles, California, United States
... and 25 more locations